# A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

> **NCT04809389** · PHASE1 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 115 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** DelNS1-nCoV-RBD LAIV
- **BIOLOGICAL:** Matching placebo

## Key facts

- **NCT ID:** NCT04809389
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-29
- **Primary completion:** 2022-09
- **Final completion:** 2022-09
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809389, "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04809389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*